DDInter513 DDInter899
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Dexamethasone {u} (Compound) resembles {v} (Compound) Fludrocortisone
Dexamethasone {u} (Compound) resembles {v} (Compound) Triamcinolone
Dexamethasone {u} (Compound) treats {v} (Disease) psoriatic arthritis
Dexamethasone {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
Dexamethasone {u} (Compound) upregulates {v} (Gene) PCYOX1L
Dexamethasone {u} (Compound) palliates {v} (Disease) kidney cancer
Dexamethasone {u} (Compound) is included by {v} (Pharmacologic Class) Corticosteroid Hormone Receptor Agonists
Dexamethasone {u} (Compound) downregulates {v} (Gene) DNAJB6
Dexamethasone {u} (Compound) causes {v} (Side Effect) Vitreous opacities
Dexamethasone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sodium bicarbonate
Dexamethasone (Compound) resembles Fludrocortisone (Compound)
Dexamethasone (Compound) resembles Triamcinolone (Compound)
Dexamethasone (Compound) treats psoriatic arthritis (Disease)
Dexamethasone (Compound) binds CYP3A7-CYP3A51P (Gene)
Dexamethasone (Compound) upregulates PCYOX1L (Gene)
Dexamethasone (Compound) palliates kidney cancer (Disease)
Dexamethasone (Compound) is included by Corticosteroid Hormone Receptor Agonists (Pharmacologic Class)
Dexamethasone (Compound) downregulates DNAJB6 (Gene)
Dexamethasone (Compound) causes Vitreous opacities (Side Effect)
Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate